Chemical & Processing
Oil & Gas
Pharma Biotech
Infrastructure & Design

Partner of Choice in Healthcare
K Nithyananda Reddy, Vice Chairman & Wholetime Director, Aurobindo Pharma says that companyís the four pronged strategy which will play key role in companyís future growth.

Aurobindo Pharma is born out of a vision of two self-made entrepreneurs Mr PV Ramprasad Reddy and K Nithyananda Reddy and a few fellow professionals 26 years back. Over a short period of time the company has earned a very distinct identity in pharma space as vertically integrated company with focus on Chemical Research, Formulation Research, Prove Bio-equivalence, Manufacturing of intermediates, active ingredients and formulations and forward integrated marketing network across the globe . Move up in the value chain strategy has enabled the company to become Partner of Choice in Healthcare for its clients.

Value Chain strategy of the company encompasses broadly robust Research and Development leading to latest in Healthcare and Extensive Manufacturing capabilities leading to partner of choice option for healthcare clients .

We have set up state- of- the- art facilities for both APIs & Formulations with access to latest equipment with sophisticated instruments and dedicated solid state characterization lab. Well qualified human capital base- over 800 scientists are involved in developing non-infringing technologies for both API and finished dosage formulations . The group has expertise in complex technologies : in house expertise in complex multistep synthesis, chiral synthesis, impurity profiling ,solid state properties evaluation, column separation technology and sterile manufacturing.

Aurobindo Pharma has gained expertise in regulatory filing and proven expertise in filing dossiers and securing approvals from more than 80 markets of the world. The company has strong knowledge based IP and has filed out a total of 513 patents out of which 325 are in chemical development and 188 in formulations; and now the company is venturing into carbohydrates & peptide chemistry.

Our 13 manufacturing facilities cater to the producing APIs & Formulations and all the facilities have received the necessary approvals from USFDA, UKMHRA, Health Canada, PMDA, MCC, ANVISA, TGA, GCC DR etc. We have an extensively diversified portfolio spread across cardiovascular, CNS, antiretroviral and antibiotics etc is enriched with over 200 APIs & 400 finished dosage formulations.

Additionally we have developed Multiple Formulation technology platforms like Immediate release/modified release tables/capsules, orally disintegrating/dissolving tablets, combination products, sterile lyophilized powder/liquids, oral liquids and dry syrups, ophthalmic solutions, inhalation solutions, chewable tablets etc.

Aurobindo Pharma is already associated with global healthcare support organizations extending large portfolio of anti-retroviral products to support global initiatives such as US presidentís Emergency plan for AIDS relief & invited by UNO to develop innovative paediatric formulations. We have very well established CRAMS facility to meet the customized requirements of global partners.

Our value chain strategy will be supported by 4 business pillars such as Corporate Values cascade based on Business care, People care and Organisation care, fostering operational excellence to provide discernible value to our customers creating a performance driven culture with heightened professionalism and accountability levels and focusing on environment, health and safety to protect the environment and safety of everyone in the company.